PropertyValue
?:abstract
  • Accumulating evidence suggests that obesity is a major risk factor for the initiation, progression, and outcomes of coronavirus disease 2019 (COVID-19). The European Association for the Study of Obesity (EASO), as a scientific and medical society dedicated to the promotion of health and well-being, is greatly concerned about the concomitant obesity and COVID-19 pandemics and their impact on health and society at large. In this perspective, we will address the inherent immunological perturbations and alterations in the renin-angiotensin-aldosterone system in patients with obesity and COVID-19, and discuss how these impairments may underlie the increased susceptibility and more detrimental outcomes of COVID-19 in people with obesity. Clearly, this has important implications for preventive measures, vaccination, and future therapeutic strategies to combat COVID-19. Furthermore, we will highlight important knowledge gaps and provide suggestions for future research and recommendations for policy actions. Since many new reports on COVID-19 rapidly appear, the present perspective should be seen as a focus for discussion to drive forward further understanding, research initiatives, and clinical management of COVID-19.
?:creator
?:doi
?:doi
  • 10.1159/000510719
?:journal
  • Obes_Facts
?:license
  • cc-by-nc-nd
?:pdf_json_files
  • document_parses/pdf_json/b8b883b8072f451bd155790807b91211e459c80f.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7490508.xml.json
?:pmcid
?:pmid
?:pmid
  • 32791497.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity
?:type
?:year
  • 2020-08-13

Metadata

Anon_0  
expand all